Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat ophthalmic diseases, with a focus on orphan and age-related retinal diseases.
Recent News View all
Various statements that Ophthotech makes on this website about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The terms 'may,' 'will,' 'could,' 'anticipate,' 'plan,' 'continue,' 'project,' 'intend,' 'estimate,' 'believe,' 'expect,' and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors.
In addition, any forward-looking statements represent the company's views only as of the date such statements are made and should not be relied upon as representing our views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaim any obligation to do so, even if its views change. Therefore, you should not rely on these forward-looking statements as representing the company's views as of any date subsequent the date such statements are made.